NYSE:MORMorphoSys Stock Price, Forecast & News

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MOR shares have increased by 30.6% and is now trading at $32.99. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MorphoSys.

MorphoSys is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for MorphoSys.

MorphoSys AG Unsponsored ADR (NYSE:MOR) posted its quarterly earnings data on Wednesday, May, 6th. The company reported $1.68 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $1.64. The company earned $277.09 million during the quarter, compared to the consensus estimate of $146.03 million. View MorphoSys' earnings history.

News stories about MOR stock have been trending somewhat negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MorphoSys earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about MorphoSys.

Some companies that are related to MorphoSys include Vir Biotechnology (VIR), BTG (BTG), Abcam (ABC), Cronos Group (CRON), Kodiak Sciences (KOD), Genus (GNS), Viela Bio (VIE), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL) and PureTech Health (PRTC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), Stemline Therapeutics (STML), TG Therapeutics (TGTX), Zymeworks (ZYME), ACADIA Pharmaceuticals (ACAD), Agenus (AGEN), Amarin (AMRN), argenx (ARGX) and Arena Pharmaceuticals (ARNA).

(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

MorphoSys trades on the New York Stock Exchange (NYSE) under the ticker symbol "MOR."

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MOR stock can currently be purchased for approximately $32.99.

MorphoSys has a market capitalization of $4.34 billion.

The official website for MorphoSys is www.morphosys.com.

The company can be reached via phone at 49 89 89927 0.